Trial · NCT01482169
Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
NCT01482169, Not applicable, Completed, Ochsner Health System; results first posted 2018-05-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR). Trials, record NCT01482169. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01482169
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
- NCT number
- NCT01482169
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 48 participants, actual
- Lead sponsor
- Ochsner Health System
- Conditions
- Coronary Artery Disease
- Interventions
- FFR Measurement with IV Adenoscan® then with Regadenoson
- First posted
- 2011-11-30
- Last updated
- 2018-05-11
- Results first posted
- 2018-05-11
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Comparing Measurement of Fractional Flow Reserve (FFR) | DAY 1 | For the first measurement of FFR, the subject will receive Adenoscan® by IV infusion. Then the FFR measurements will be taken. When vital signs have returned to normal, after two minutes the line will be flushed with saline. The subject will then receive Regadenoson by IV infusion and repeat FFR measurements will be recorded. The subject will be administered aminophylline and the time duration it takes to return to baseline hemodynamic will be recorded. |
| Secondary | Duration to Baseline Hyperemia After Aminophylline Injection | seconds | In the regadenoson arm, the duration to baseline hyperemia after aminophylline Injection |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Comparing Measurement of Fractional Flow Reserve (FFR) | DAY 1 | FFR | MEAN | |
| SECONDARY | Duration to Baseline Hyperemia After Aminophylline Injection | seconds | Of the 48 patients enrolled, 7 of the patients did not have measurements for the secondary outcome. | seconds | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Comparing Measurement of Fractional Flow Reserve (FFR) | Adenoscan | .83 | Standard Deviation 0.082 | FFR | |
| Comparing Measurement of Fractional Flow Reserve (FFR) | Regadenoson | .84 | Standard Deviation 0.084 | FFR | |
| Duration to Baseline Hyperemia After Aminophylline Injection | Duration to Baseline Hyperemia After Aminophylline Administrat | 112 | Standard Deviation 72 | seconds |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Adenoscan + Regadenoson | 48 | |
| Overall Study | COMPLETED | Adenoscan + Regadenoson | 46 | |
| Overall Study | NOT COMPLETED | Adenoscan + Regadenoson | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adenoscan | ||
| Total, all-cause mortality | Regadenson | ||
| Total, other adverse events | Adenoscan | 0 | 48 |
| Total, other adverse events | Regadenson | 0 | 48 |
| Total, serious adverse events | Adenoscan | 0 | 48 |
| Total, serious adverse events | Regadenson | 0 | 48 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Adenoscan vs Regadenson: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01482169
GET https://conductscience.org/api/trials/v1/NCT01482169/registered